Literature DB >> 15938644

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.

Arianna Donella-Deana1, Oriano Marin, Luca Cesaro, Rosalind H Gunby, Anna Ferrarese, Addolorata M L Coluccia, Carmen J Tartari, Luca Mologni, Leonardo Scapozza, Carlo Gambacorti-Passerini, Lorenzo A Pinna.   

Abstract

The anaplastic lymphoma kinase (ALK), whose constitutively active fusion proteins are responsible for 5-10% of non-Hodgkin's lymphomas, shares with the other members of the insulin receptor kinase (IRK) subfamily an activation loop (A-loop) with the triple tyrosine motif Y-x-x-x-Y-Y. However, the amino acid sequence of the ALK A-loop differs significantly from the sequences of both the IRK A-loop and the consensus A-loop for this kinase subfamily. A major difference is the presence of a unique "RAS" triplet between the first and second tyrosines of the ALK A-loop, which in IRK is replaced by "ETD". Here we show that a peptide reproducing the A-loop of ALK is readily phosphorylated by ALK, while a homologous IRK A-loop peptide is not unless its "ETD" triplet is substituted by "RAS". Phosphorylation occurs almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif, as judged by Edman analysis of the phosphoradiolabeled product. Consequently, a peptide in which the first tyrosine had been replaced by phenylalanine (FYY) was almost unaffected by ALK. In contrast, a peptide in which the second and third tyrosines had been replaced by phenylalanine (YFF) was phosphorylated more rapidly than the parent peptide (YYY). A number of substitutions in the YFF peptide outlined the importance of Ile and Arg at positions n - 1 and n + 6 in addition to the central triplet, to ensure efficient phosphorylation by ALK. Such a peculiar substrate specificity allows the specific monitoring of ALK activity in crude extracts of NPM-ALK positive cells, using the YFF peptide, which is only marginally phosphorylated by a number of other tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15938644     DOI: 10.1021/bi0472954

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

2.  A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target.

Authors:  Aya Wakata; Sean M Cahill; Michael Blumenstein; Rosalind H Gunby; Steffen Jockusch; Angel A Marti; Barbara Cimbro; Carlo Gambacorti-Passerini; Arianna Donella-Deana; Lorenzo A Pinna; Nicholas J Turro; David S Lawrence
Journal:  Org Lett       Date:  2007-12-18       Impact factor: 6.005

3.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

4.  A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.

Authors:  Wei Cui; Laurie L Parker
Journal:  Chem Commun (Camb)       Date:  2014-11-18       Impact factor: 6.222

5.  Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.

Authors:  Lindsey M Kelly; Guillermo Barila; Pengyuan Liu; Viktoria N Evdokimova; Sumita Trivedi; Federica Panebianco; Manoj Gandhi; Sally E Carty; Steven P Hodak; Jianhua Luo; Sanja Dacic; Yan P Yu; Marina N Nikiforova; Robert L Ferris; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

6.  The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Authors:  Linda F Epstein; Hao Chen; Renee Emkey; Douglas A Whittington
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

7.  NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.

Authors:  C A Murga-Zamalloa; V Mendoza-Reinoso; A A Sahasrabuddhe; D Rolland; S R Hwang; S R P McDonnell; A P Sciallis; R A Wilcox; V Bashur; K Elenitoba-Johnson; M S Lim
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

8.  Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.

Authors:  Peng Wang; Fang Wu; Yupo Ma; Liang Li; Raymond Lai; Leah C Young
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

9.  Modulation of protein kinase CK2 activity by fragments of CFTR encompassing F508 may reflect functional links with cystic fibrosis pathogenesis.

Authors:  Mario A Pagano; Giorgio Arrigoni; Oriano Marin; Stefania Sarno; Flavio Meggio; Kate J Treharne; Anil Mehta; Lorenzo A Pinna
Journal:  Biochemistry       Date:  2008-07-03       Impact factor: 3.162

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.